Oncology

Mounting concerns about availability of cancer drugs raise questions about the current supply

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

Chemotherapy may increase inflammatory biomarkers that can impact the diversity of the gut microbiome, leading to serious anthropomorphic changes among women treated for early-stage breast cancer.

A panel at the Advanced Topics for Oncology Pharmacy Professionals Summit discusses strategies to address patients’ fears and distrust of the medical and scientific community.

Effective implementation of the Inflation Reduction Act may allow legislators to shift their focus toward controversial pharmacy benefit manager practices, according to a panel discussion during the ATOPP Summit.

A cancer vaccine has shown efficacy in dogs, with implications for benefit in humans.

Zanubrutinib combined with obinutuzumab was previously granted both Fast Track and Orphan drug designations for patients with relapsed or refractory follicular lymphoma.

Despite a slew of barriers with patient management, pharmacists have the training and resources to advocate for better patient care and help patients with hematologic myeloproliferative neoplasms advocate for themselves.

Because of its prevalence in approximately 50% of breast cancers, the outcomes of HER2-low treatment have a significant impact on patient outcomes.

Updated phase 3 trial data provide practice-changing findings.

These study results may inform clinical practice strategies this year and beyond.

Irreversible Bruton tyrosine kinase inhibitor produces positive results in patients with relapsed/refractory marginal zone lymphoma.

Nivolumab-based combinations have shown significant survival benefits across several tumor types, including melanoma and advanced renal cell carcinoma.

Study shows equivalent overall survival among younger adults with acute lymphoblastic leukemia aged 15 to 29 and older adults aged 30 to 50 with normal BMI.

The landscape of clinical trials in oncology is rapidly evolving, driven by increasing research efforts and advancements in the field of clinical research.

Institutional review boards and ethics committees have seen it as their main task in the past few decades to protect children from questionable studies; however, they are faced with a new challenge with pediatric drug development.

Diagnostic technologies are advancing quickly, which may lead to therapeutics for age-related diseases to safely reduce chronic low-grade inflammation generated by the immune system.

Oncology pharmacy is best learned in real time with real oncologists and real patients.

Trial shows an improved survival rate at 4 years when treated with the STRIDE regimen in comparison to treatment with sorafenib in patients with unresectable hepatocellular carcinoma.

Pirtobrutinib is a non–covalent (reversible) BTK inhibitor, demonstrating a 73.3% overall response rate with a median follow-up of 19.4 months among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Despite recommendations for adults to receive lung cancer screenings, rates have remained low compared with other cancer screening programs.

More than half of the patients prescribed oral anticancer agents report persistent moderate-to-severe symptoms, despite receiving counseling on adverse effect management.

Pharmacists must find innovative health care solutions to combat the hefty financial burden associated with treating cancer.

The American Society of Clinical Oncology (ASCO) Annual Meeting includes updates from some of the most important clinical trials being conducted in the field of oncology.

Researchers noted that the therapy remains risky, owing to the substantial immunosuppressive and cytopenic effects of the trial protocol and the risks that immune-cell manipulation carries.

The recommended addition is based on a uniform consensus that the therapy is an appropriate treatment for this difficult-to-treat disease.

Investigators call for further public awareness of other breast cancer risk factors, besides dense breasts, which could help identify more women who are at high risk.

Investigators found that the first biosimilar of trastuzumab, trastuzumab-anns (Kanjinti; Amgen), did maintain a strong and persistent advantage over the other 4 biosimilar entrants.

The microRNA member miR-204-5p inhibits apoptosis in melanoma cells treated with dacarbazine or when overexpressed.

Race, ethnicity, years after diagnosis and mental and physical stress are among factors associated with unmet supportive care needs and a higher risk of hospitalization among patients with cancer.